Circulating PANDER Concentration is Associated with Increased HbA1c and Fasting Blood Glucose in Type 2 Diabetic Subjects

Overview

Journal J Clin Transl Endocrinol

Specialty Endocrinology

Date 2018 Apr 25

PMID 29686968

Citations 6

Authors

Catherine B MarElia

Melanie N Kuehl

Tiffany A Shemwell

Amy C Alman

Brant R Burkhardt

Affiliations

Soon will be listed here.

Abstract

Aim: PANcreatic-DERived factor (PANDER, FAM3B) is a novel hormone that regulates glucose levels via interaction with both the endocrine pancreas and liver. Prior studies examining PANDER were primarily conducted in murine models or but little is known regarding the circulating concentration of PANDER in humans, especially with regard to the association of type 2 diabetes (T2D) or overall glycemic regulation. To address this limitation, we performed a cross-sectional analysis of circulating serum PANDER concentration in association with other hormones that serve as either markers of insulin resistance (insulin and adiponectin) or to metabolic parameters of glycemic control such as fasting HbA1c and blood glucose (FBG).

Methods: Fasting serum was obtained from a commercial biorepository from 300 de-identified adult subjects with 150 T2D and non-T2D adult subjects collected from a population within the United States, respectively, matched on gender, age group and race/ethnicity. Concentration of PANDER, insulin and adiponectin were measured for all samples as determined by commercial ELISA. Metadata was provided for each subject including demography, anthropometry, and cigarette and alcohol use. In addition, fasting blood glucose (FBG) and HbA1c were available on T2D subjects.

Results: Multiple linear regression analyses were performed to examine the relationships between circulating log PANDER concentration on HbA1c, fasting glucose, log insulin, log HOMA-β and log HOMA-IR among T2D subjects and for insulin and adiponectin in non-T2D subjects. A significant linear association was identified between PANDER with fasting HbA1c (β 0.832 ± SE 0.22, p = 0.0003) and FBG (β 20.66 ± SE 7.43, p = 0.006) within T2D subjects. However, insulin, HOMA-β, HOMA-IR and adiponectin (p > 0.05) were not found to be linearly associated with PANDER concentration.

Conclusion: Within T2D subjects, PANDER is modestly linearly associated with increased HbA1c and FBG in a US population. In addition, highest circulating PANDER levels were measured in T2D subjects with HbA1c above 9.9. No association was identified with PANDER and insulin resistance or pancreatic β-cell function in T2D subjects.

Citing Articles

The role of PANDER and its interplay with IL-6 in the regulation of GLP-1 secretion.

Li Z, Pei L, Xiao H, Chen N, Lai F, Yue S Endocr Connect. 2024; 13(11).

PMID: 39235859 PMC: 11466252. DOI: 10.1530/EC-23-0548.

Relationship between Cytokines and Metabolic Syndrome Components: Role of Pancreatic-Derived Factor, Interleukin-37, and Tumor Necrosis Factor-α in Metabolic Syndrome Patients.

Abdel-Moneim A, Mahmoud R, Allam G, Mahmoud B Indian J Clin Biochem. 2024; 39(1):37-46.

PMID: 38223016 PMC: 10784435. DOI: 10.1007/s12291-022-01079-z.

Inter-organ crosstalk during development and progression of type 2 diabetes mellitus.

Xourafa G, Korbmacher M, Roden M Nat Rev Endocrinol. 2023; 20(1):27-49.

PMID: 37845351 DOI: 10.1038/s41574-023-00898-1.

Periodontitis and cardiovascular risk factors in subjects with and without type 1 diabetes: A cross sectional analysis.

Bailey R, Sarkar A, Snell-Bergeon J, Burkhardt B, Chandrasekaran S, Johnson L J Diabetes Complications. 2023; 37(7):108494.

PMID: 37209505 PMC: 10601755. DOI: 10.1016/j.jdiacomp.2023.108494.

The cytokine FAM3B/PANDER is an FGFR ligand that promotes posterior development in .

Zhang F, Zhu X, Wang P, He Q, Huang H, Zheng T Proc Natl Acad Sci U S A. 2021; 118(20).

PMID: 33975953 PMC: 8158011. DOI: 10.1073/pnas.2100342118.

References

Yang J, Guan Y . Family with sequence similarity 3 gene family and nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 2013; 28 Suppl 1:105-11. DOI: 10.1111/jgh.12033. View

Brochu-Gaudreau K, Rehfeldt C, Blouin R, Bordignon V, Murphy B, Palin M . Adiponectin action from head to toe. Endocrine. 2010; 37(1):11-32. DOI: 10.1007/s12020-009-9278-8. View

Ratliff W, Athanason M, Chechele A, Kuehl M, Fernandez A, MarElia C . Hepatic nutrient and hormonal regulation of the PANcreatic-DERived factor (PANDER) promoter. Mol Cell Endocrinol. 2015; 413:101-12. DOI: 10.1016/j.mce.2015.05.040. View

Robert-Cooperman C, Carnegie J, Wilson C, Yang J, Cook J, Wu J . Targeted disruption of pancreatic-derived factor (PANDER, FAM3B) impairs pancreatic beta-cell function. Diabetes. 2010; 59(9):2209-18. PMC: 2927943. DOI: 10.2337/db09-1552. View

Diez J, Iglesias P . The role of the novel adipocyte-derived protein adiponectin in human disease: an update. Mini Rev Med Chem. 2010; 10(9):856-69. DOI: 10.2174/138955710791608325. View

Kadowaki T, Yamauchi T . Adiponectin and adiponectin receptors. Endocr Rev. 2005; 26(3):439-51. DOI: 10.1210/er.2005-0005. View

Wilson C, Robert-Cooperman C, Burkhardt B . PANcreatic-DERived factor: novel hormone PANDERing to glucose regulation. FEBS Lett. 2011; 585(14):2137-43. PMC: 5789785. DOI: 10.1016/j.febslet.2011.05.059. View

Brown M, Goldstein J . Selective versus total insulin resistance: a pathogenic paradox. Cell Metab. 2008; 7(2):95-6. DOI: 10.1016/j.cmet.2007.12.009. View

Athanason M, Stevens Jr S, Burkhardt B . Hepatic SILAC proteomic data from PANDER transgenic model. Data Brief. 2016; 9:159-62. PMC: 5018088. DOI: 10.1016/j.dib.2016.08.017. View

10.

Li S, Shin H, Ding E, van Dam R . Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009; 302(2):179-88. DOI: 10.1001/jama.2009.976. View

11.

Wang C, Burkhardt B, Guan Y, Yang J . Role of pancreatic-derived factor in type 2 diabetes: evidence from pancreatic β cells and liver. Nutr Rev. 2012; 70(2):100-6. DOI: 10.1111/j.1753-4887.2011.00457.x. View

12.

Biddinger S, Hernandez-Ono A, Rask-Madsen C, Haas J, Aleman J, Suzuki R . Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab. 2008; 7(2):125-34. PMC: 4251554. DOI: 10.1016/j.cmet.2007.11.013. View

13.

Li J, Chi Y, Wang C, Wu J, Yang H, Zhang D . Pancreatic-derived factor promotes lipogenesis in the mouse liver: role of the Forkhead box 1 signaling pathway. Hepatology. 2011; 53(6):1906-16. DOI: 10.1002/hep.24295. View

14.

Cao X, Yang C, Lai F, Hong Z, Lin H, Liu J . Elevated circulating level of a cytokine, pancreatic-derived factor, is associated with metabolic syndrome components in a Chinese population. J Diabetes Investig. 2016; 7(4):581-6. PMC: 4931209. DOI: 10.1111/jdi.12437. View

15.

Robert-Cooperman C, Dougan G, Moak S, Athanason M, Kuehl M, Bell-Temin H . PANDER transgenic mice display fasting hyperglycemia and hepatic insulin resistance. J Endocrinol. 2014; 220(3):219-31. DOI: 10.1530/JOE-13-0338. View

16.

Calton E, Miller V, Soares M . Factors determining the risk of the metabolic syndrome: is there a central role for adiponectin?. Eur J Clin Nutr. 2013; 67(5):485-91. DOI: 10.1038/ejcn.2013.1. View

17.

Cao X, Gao Z, Robert C, Greene S, Xu G, Xu W . Pancreatic-derived factor (FAM3B), a novel islet cytokine, induces apoptosis of insulin-secreting beta-cells. Diabetes. 2003; 52(9):2296-303. DOI: 10.2337/diabetes.52.9.2296. View

18.

Robert-Cooperman C, Wilson C, Burkhardt B . PANDER KO mice on high-fat diet are glucose intolerant yet resistant to fasting hyperglycemia and hyperinsulinemia. FEBS Lett. 2011; 585(9):1345-9. PMC: 5754927. DOI: 10.1016/j.febslet.2011.04.005. View

19.

Xu W, Gao Z, Wu J, Wolf B . Interferon-gamma-induced regulation of the pancreatic derived cytokine FAM3B in islets and insulin-secreting betaTC3 cells. Mol Cell Endocrinol. 2005; 240(1-2):74-81. DOI: 10.1016/j.mce.2005.05.010. View

20.

Zhu Y, Xu G, Patel A, McLaughlin M, Silverman C, Knecht K . Cloning, expression, and initial characterization of a novel cytokine-like gene family. Genomics. 2002; 80(2):144-50. DOI: 10.1006/geno.2002.6816. View